Cart 0

News

Performing risk assessments for the risk-based monitoring of clinical trials

Performing risk assessments for the risk-based monitoring of clinical trials

Risk assessment is an integral part of risk management. In clinical trials, it serves to lay the foundation of risk-based monitoring processes. Regulators currently encourage its use to improve the safety and the quality of clinical trials. In practice, assessing risks is difficult but clinical research professionals must become acquainted with the concept of risk assessment in order to reap the full potential of risk-based monitoring. Regulatory Perspective The FDA’s most recent guidance is fairly specific about the importance of conducting a risk assessment to identify risk and develop a monitoring plan: The risk assessment serves to identify and understand...

Read more →


What's In a Centralized Monitoring Report

What's In a Centralized Monitoring Report

The centralized monitoring report is the best channel to share risk signals with clinical trials stakeholders. In addition to being the perfect tool for the review of site-specific Key Risk Indicators (KRI) metrics with clinical operations teams, producing periodic reports ensures the traceability of the centralized monitoring activities for regulatory audit purpose. Reports are also essential for the continuous improvement of centralized monitoring processes.   The TransCelerate BioPharma Initiative specifically states that Monitoring reports should serve as tools for the team members to communicate a concise, high-level summary of monitoring activities, issues and associated actions.  It’s imperative that companies build off...

Read more →


Setting Limits in Centralized Monitoring

Setting Limits in Centralized Monitoring

When using a centralized monitoring approach, Key Risk Indicators (KRIs) metrics are calculated for individual study sites and compared against limits, also known as “thresholds” or “tolerance level”, beyond which sites may be considered abnormal and warrant investigation. Limit values must be carefully chosen to be able to detect risk without triggering too many false signals. Information relevant to the choice of limits can be obtained by executing a trial’s risk assessment and by calculating site-specific KRIs statistical distributions. Below are some points to consider when choosing limits. Limits Based on Risk Assessment Risk identified through the risk assessment should...

Read more →


Planning for Change in Centralized Monitoring

Planning for Change in Centralized Monitoring

Writing an Integrated Quality and Risk Management Plan (IQRMP) involves identifying risk factors and developing a contingency plan to manage the risks that cannot be eliminated. Risk factors can be monitored using Key Risk Indicators (KRI) which are metrics calculated from the collected data associated with risk factors. For instance, most studies consider the AE rate a risk factor and will monitor it on a periodic basis by calculating the site-specific number of adverse events divided by the number of subject-days. A risk signal is typically triggered when a Key Risk Indicator (KRI) metric’s value falls beyond its set limits...

Read more →


Centralized Monitoring False Risk Signals

Centralized Monitoring False Risk Signals

Performing clinical trial Centralized Monitoring (CM) involves evaluating risk signals such as site-specific Key Risk Indicators (KRI) metrics that fall outside set limits and monitoring their progress. Many systems use dashboards with traffic lights-type risk signals to highlight sites with computed KRI metrics values that fall outside their normal range. When these lights are triggered, they usually initiate a sequence of actions by the clinical team aimed at mitigating the risk they represent. Nevertheless, upon closer examination, it appears that most risk signals are the result of perfectly normal phenomena and actually requires no action by the clinical team. Here...

Read more →